Aug 25 (Reuters) - Genetic Signatures Ltd (GSS) : INFLUENZA B...

Aug 25 (Reuters) - Genetic Signatures Ltd (GSS) :

• INFLUENZA B DETECTION EXPECTED TO IMPACT ON QUARTER SALES
• A UNDERTAKEN AN INVESTIGATION
• WELL-ADVANCED IN RESOLVING THE ISSUE, WHICH IS SPECIFIC TO INFLUENZA B VIRUS
• FOUND SEASON'S INFLUENZA B VIRUS IS NOT BEING CONSISTENTLY DETECTED IN A SMALL PROPORTION OF LOW VIRAL CONCENTRATION SAMPLES
• AT THIS TIME, WE EXPECT FORECAST REVENUE TO BE ABOUT A$2 MILLION FOR Q1 FY2023
• DETECTION OF INFLUENZA A VIRUS IS UNAFFECTED.
• IN INTERIM, SALE OF GENETIC SIGNATURES EASYSCREEN™ RESPIRATORY PATHOGEN DETECTION KIT HAS BEEN IMPACTED DURING THIS CURRENT QUARTER